Clinical Trial Detail

NCT ID NCT02614508
Title Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

CLL/SLL

Therapies

Buparlisib + Ibrutinib

Buparlisib + Ofatumumab

Age Groups: adult

No variant requirements are available.